Results 161 to 170 of about 2,169 (197)
Some of the next articles are maybe not open access.
Clinical Application of Risdiplam in 5q Spinal Muscular Atrophy: A Narrative Review
British Journal of Hospital Medicine5q spinal muscular atrophy (SMA) is caused by mutations in the survival motor neuron (SMN) gene located on chromosome 5, leading to insufficient SMN protein levels. Risdiplam is an RNA splicing modifier that modifies pre-mRNA splicing of the SMN2 gene, thereby promoting the production of functional survival motor neuron protein (SMN-fl).
Tong, Zhao +4 more
openaire +2 more sources
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls
New England Journal of Medicine, 2021Riccardo Masson +2 more
exaly
Zulassungserweiterung für Risdiplam
DNP – Die Neurologie & Psychiatrie, 2023openaire +1 more source
Orale Therapie der SMA mit Spleißmodulator Risdiplam
DNP - Der Neurologe & Psychiater, 2022Svenja Brakemeier, Tim Hagenacker
openaire +1 more source
P.113 Safety update: Risdiplam clinical trial development program
Neuromuscular Disorders, 2022Chiriboga, Claudia A. +19 more
openaire +2 more sources

